0TB Stock Overview
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0TB from our risk checks.
Theravance Biopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.05 |
52 Week High | US$10.70 |
52 Week Low | US$7.60 |
Beta | 0.35 |
1 Month Change | 14.56% |
3 Month Change | 2.84% |
1 Year Change | -15.42% |
3 Year Change | -49.72% |
5 Year Change | -55.42% |
Change since IPO | -53.55% |
Recent News & Updates
Recent updates
Shareholder Returns
0TB | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 4.0% | -1.0% | -1.7% |
1Y | -15.4% | -30.1% | 1.4% |
Return vs Industry: 0TB exceeded the German Pharmaceuticals industry which returned -30.1% over the past year.
Return vs Market: 0TB underperformed the German Market which returned 1.4% over the past year.
Price Volatility
0TB volatility | |
---|---|
0TB Average Weekly Movement | 5.7% |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 9.8% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0TB has not had significant price volatility in the past 3 months.
Volatility Over Time: 0TB's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 99 | Rick Winningham | www.theravance.com |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
Theravance Biopharma, Inc. Fundamentals Summary
0TB fundamental statistics | |
---|---|
Market cap | €453.29m |
Earnings (TTM) | -€51.94m |
Revenue (TTM) | €54.04m |
8.4x
P/S Ratio-8.7x
P/E RatioIs 0TB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0TB income statement (TTM) | |
---|---|
Revenue | US$57.42m |
Cost of Revenue | US$40.62m |
Gross Profit | US$16.80m |
Other Expenses | US$72.00m |
Earnings | -US$55.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.14 |
Gross Margin | 29.26% |
Net Profit Margin | -96.11% |
Debt/Equity Ratio | 0% |
How did 0TB perform over the long term?
See historical performance and comparison